Olon obtains CEP (Certification of Suitability to the Monographs of the European Pharmacopoeia) for its retinoid Adapalene, further strengthening its global leadership position as a supplier of this active ingredient class.
The Olon Group, a world leader in the production of active ingredients, has reached an important milestone in the expansion and consolidation of its presence in the global retinoid market, where it is a historical leader thanks to a product portfolio that includes all the main active ingredients in this class.
Olon has announced that it has also obtained CEP for Adapalene, making it one of the few European manufacturers to offer this certification. The CEP significantly reduces market access times and simplifies market entry both in Europe and in countries outside the European Union covered by the CEP.
In addition to Adapalene, the company’s pipeline includes Tretinoin, Isotretinoin, Alitretinoin, Tazarotene, Acitretin, and Trifarotene. The retinoid pipeline is also a priority of R&D strategy, to support further development and expansion.
Adapalene, like the other retinoids in the pipeline, is an active ingredient used globally in dermatological treatments.